<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04133545</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol_3525</org_study_id>
    <nct_id>NCT04133545</nct_id>
  </id_info>
  <brief_title>Discontinuation for Oral Anticoagulants in Patients With Atrial Fibrillation</brief_title>
  <official_title>Discontinuation for Oral Anticoagulants During the First Year of Use in Patients With Atrial Fibrillation Covered by a Medical Insurance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the discontinuation rates for vitamin K antagonists
      and for direct oral anticoagulants during their first year
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the discontinuation rates for vitamin K antagonists
      and for direct oral anticoagulants during their first year of use after their initiation
      during hospitalization in patients covered by our health insurance plan.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 4, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anticoagulant Discontinuation Rate</measure>
    <time_frame>One year</time_frame>
    <description>Anticoagulant Discontinuation Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Discontinuation Predictors</measure>
    <time_frame>One year</time_frame>
    <description>Discontinuation Predictors</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">360</enrollment>
  <condition>Auricular Fibrillation</condition>
  <condition>Anticoagulant Drugs</condition>
  <arm_group>
    <arm_group_label>DOAC</arm_group_label>
    <description>Direct oral anticoagulant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OAC</arm_group_label>
    <description>Vitamin K anticoagulant</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients belonging to a Health Management Organization suffering from atrial fibrillation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient older than 18 years of age covered by our Health Care Insurance Plan.

          2. Indication for oral anticoagulation with an expected duration of use of no less than 1
             year.

        Exclusion Criteria:

          1. Refusal to take part.

          2. Use of oral anticoagulants within 6 months prior to admission.

          3. Presence of mechanical prosthetic valve.

          4. Chronic renal failure with creatinine clearance &lt;30 mL/min (estimated using the MDRD
             formula).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose L Navarrro Estrada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Italiano de Buenos Aires</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1199ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2019</study_first_posted>
  <last_update_submitted>October 17, 2019</last_update_submitted>
  <last_update_submitted_qc>October 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Italiano de Buenos Aires</investigator_affiliation>
    <investigator_full_name>JOSE LUIS CARLOS NAVARRO</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

